Page 2 - ஜேம்ஸ் கிஷுே News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜேம்ஸ் கிஷுே. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜேம்ஸ் கிஷுே Today - Breaking & Trending Today

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for the Treatment of Complement Dysregulation Diseases

Posted on
228
CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that its Investigational New Drug (IND) application for CAN106, a recombinant human monoclonal antibody targeting complement C5 of the complement system, has been approved by the Health Sciences Authority (HSA) in Singapore for the treatment of complement dysregulation diseases. The first indication is paroxysmal nocturnal hemoglobinuria (PNH), a fatal disease in which the complement system destroys red blood cells.
CAN106 is being developed for multiple diseases associated with complement dysregulation. The complement system is the part of the immune system that helps antibodies and phagocytic cells clear microbes and damaged cells. Dysregulation of the proteins that compose it leads to several rare diseases, including PNH. CANbridge holds the proprie ....

Chris Chen , James Xue , Health Sciences Authority , Umass Medical School , Canbridge Pharmaceuticals Inc , Horae Gene Therapy Center , Pharmaceuticals Inc , Investigational New Drug , Wuxi Biologics , Wuxi Biologic , Paroxysmal Nocturnal Hemoglobinuria , Rare Diseases Diagnosis , Medical School , Puma Biotechnology , கிறிஸ் சென் , ஜேம்ஸ் கிஷுே , ஆரோக்கியம் அறிவியல் அதிகாரம் , உமஸ்ஸ் மருத்துவ பள்ளி , கான்பிரிட்ஜ் மருந்துகள் இன்க் , மருந்துகள் இன்க் , ரேர் நோய்கள் நோயறிதல் , மருத்துவ பள்ளி , பூமா உயிரி தொழில்நுட்பவியல் ,

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for the Treatment of Complement Dysregulation Diseases

Published: Dec 18, 2020
BEIJING & CAMBRIDGE, Mass. (BUSINESS WIRE) CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that its Investigational New Drug (IND) application for CAN106, a recombinant human monoclonal antibody targeting complement C5 of the complement system, has been approved by the Health Sciences Authority (HSA) in Singapore for the treatment of complement dysregulation diseases. The first indication is paroxysmal nocturnal hemoglobinuria (PNH), a fatal disease in which the complement system destroys red blood cells.
CAN106 is being developed for multiple diseases associated with complement dysregulation. The complement system is the part of the immune system that helps antibodies and phagocytic cells clear microbes and damaged cells. Dysregulation of the proteins that compose it leads to several rare diseases, including PNH. CANbridge holds the proprietary gl ....

Chris Chen , James Xue , Umass Medical School , Canbridge Pharmaceuticals Inc , Horae Gene Therapy Center , Wuxi Biologics , Wuxi Biologic , Paroxysmal Nocturnal Hemoglobinuria , Rare Diseases Diagnosis , Medical School , Puma Biotechnology , கிறிஸ் சென் , ஜேம்ஸ் கிஷுே , உமஸ்ஸ் மருத்துவ பள்ளி , கான்பிரிட்ஜ் மருந்துகள் இன்க் , ரேர் நோய்கள் நோயறிதல் , மருத்துவ பள்ளி , பூமா உயிரி தொழில்நுட்பவியல் ,